Anatomic Pathology Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 6.50 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Anatomic Pathology Market Analysis
The anatomical pathology market is expected to register a CAGR of 6.5% during the forecast period.
The COVID-19 outbreak impacted every aspect of the diagnostics industry, including the anatomic pathology market. During the initial pandemic, the number of patient visits to hospitals reduced significantly despite emergency services being available in hospitals. For instance, according to an article published by BMC Health Services Research in February 2022, a study was conducted in the Netherlands, which showed that the initial COVID-19 pandemic significantly impacted diagnostic pathology or anatomic pathology in the country. Thus, the COVID-19 pandemic significantly impacted the market initially. However, as the pandemic has subsided, cancer diagnosis procedures are taking place normally. Hence, the studied market is expected to have stable growth during the forecast period of the study.
Factors that are driving the market growth are the high incidence of cancer and other target diseases, the growing focus on personalized medicine, and the high usage of advanced pathology equipment.
The rising prevalence of cancer is a major factor driving the market growth, as anatomic pathology is used for the diagnosis of these diseases. For instance, according to the data published by the Spanish Network of Cancer Registries in January 2021, an estimated 0.28 million new cases of cancer were expected in Spain in 2021, out of which 43.6 thousand colorectal cancer cases, 35.8 thousand prostate cancer cases, and 33.4 thousand breast cancer cases were expected.
Moreover, according to the data published by the National Cancer Center Japan in June 2022, an estimated 1,019,000 new cases of cancer were expected in Japan in 2022, out of which 158,200 were new cases of colon/rectum cancer, 132,100 cases of stomach cancer, 128,800 cases of lung/trachea cancer, 96,400 cases of prostate cancer, and 95,000 cases of breast cancer. Thus, the greater incidence of cancers has increased the demand for various anatomic pathology products for the diagnosis of cancers.
Additionally, the rising developments by various organizations are also expected to enhance market growth. For instance, in October 2022, pathologists from Europe, Japan, and the United States jointly debuted the Digital Pathology Connections (DPC), a global community for professionals interested in the digital future of the anatomic pathology laboratory.
Thus, the aforementioned factors, such as the rising prevalence of cancer, increasing demand for personalized medicines, and the rising developments by various organizations, are expected to enhance the market growth. However, stringent government regulations pertaining to anatomic pathology and the lack of skilled professionals are expected to hinder market growth.
Anatomic Pathology Market Trends
The Consumables Segment is Expected to Witness Significant Growth Over the Forecast Period
The consumables segment is expected to hold a significant market share during the forecast period. The availability of a wide range of products, coupled with a high usage rate of consumables in research findings, is fueling the segment's growth. The low cost and the easy availability of pathology consumables further contributed to the segment's growth. Moreover, the rising prevalence of cancer is a major factor expected to enhance the usage of anatomic pathology consumables.
For instance, according to the data updated by Cancer Australia in January 2021, it was estimated that 20,640 new cases of cancer will be diagnosed in Australia during 2022, which will account for 12.7% of the new cancer cases diagnosed in the country. The source also stated that breast cancer would be the second most commonly diagnosed cancer in 2022 in Australia. Thus, the high prevalence of breast cancer is expected to boost segment growth.
Moreover, the rising cancer screening is also expected to increase the consumption of consumables used in anatomic pathology procedures such as biopsies. For instance, according to the data updated by the Office for Health Improvement and Disparities in 2022, an estimated 6,446,929 screening procedures took place in the United Kingdom during 2021-22 for colorectal cancer diagnosis.
Additionally, the rising developments by major market players are also expected to enhance the segment's growth. For instance, in June 2022, EmeritusDX, a rapidly growing cancer diagnostics and information company, acquired Freedom Pathology Partners to expand its national presence in Anatomic Pathology, fluorescence in situ hybridization, and molecular testing. This is expected to increase access to anatomic pathology consumables during the forecast period of the study.
Thus, the aforementioned factors, such as the rising prevalence of cancer and the rising developments by key market players, are expected to enhance market growth.
North America is Expected to Hold a Significant Share in the Market Over the Forecast Period
North America accounted for a significant revenue share due to the presence of major players and supportive government initiatives pertaining to training pathological programs. There is also easy accessibility to advanced technologies, government initiatives for screening cancer patients, favorable reimbursement scenarios for anatomic pathology diagnostic tests, increasing healthcare expenditure, and the presence of high-quality infrastructure for hospitals and clinical laboratories in the region, which are the major factors driving the growth of the anatomic pathology market in North America.
For instance, as per the Canada Cancer Society's statistics for 2022, around 6,700 Canadians were diagnosed with leukemia in 2021, out of which 4,000 were men and 2,700 were women. Also, as per the American Cancer Society's data for 2023, around 59,610 new cases of leukemia and 20,380 new cases of acute myeloid leukemia (AML) are expected to be diagnosed in the United States in 2023. Thus, the high incidence of cancer cases is leading to an increase in the usage of anatomic pathology diagnosis, thereby driving the market in the region.
Furthermore, key entities are undertaking several strategic initiatives to develop upgraded and advanced pathology devices concerning their design and ease of use. For instance, in July 2022, BillionToOne, a United States-based company, launched its first oncology liquid biopsy products, Northstar Select and Northstar Response. As biopsy is considered an anatomic pathology procedure, the launch of such products is expected to enhance the market growth in the region.
Thus, the aforementioned factors, such as the rising prevalence of cancer and the rising developments by key market players, are expected to enhance market growth.
Anatomic Pathology Industry Overview
The studied market is moderately fragmented in nature. Product innovation and ongoing R&D activities to develop advanced technologies have helped in boosting the growth of the market. The strategies implemented include collaborative development, business expansion, and product development. Some of the key players operating in the market are Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, F. Hoffmann-La Roche Ltd., Laboratory Corporation of America Holdings, and Agilent Technologies, Inc., among others.
Anatomic Pathology Market Leaders
-
Thermo Fisher Scientific Inc.
-
Quest Diagnostics Incorporated
-
F. Hoffmann-La Roche Ltd.
-
Laboratory Corporation of America Holdings
-
Agilent Technologies, Inc.
*Disclaimer: Major Players sorted in no particular order
Anatomic Pathology Market News
- September 2022: Epredia's parent company, PHC Holdings Corporation, acquired anatomical pathology suppliers Microm Microtech France and Laurypath in a strategic expansion of Epredia's presence in Europe.
- June 2022: Roche launched the VENTANA DP 600 slide scanner for digital pathology, enhancing patient care with precision diagnostics. This is used in anatomic pathology.
Anatomic Pathology Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 High Incidence of Cancer and Other Target Diseases
- 4.2.2 Growing Focus on Personalized Medicine
- 4.2.3 High Usage of Advanced Pathology Equipment
-
4.3 Market Restraints
- 4.3.1 Stringent Government Regulations Pertaining to Anatomic Pathology
- 4.3.2 Lack of Skilled Professionals
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size - Value in USD million)
-
5.1 By Product & Services
- 5.1.1 Instruments
- 5.1.2 Consumables
- 5.1.3 Services
-
5.2 By Application
- 5.2.1 Disease Diagnosis
- 5.2.2 Drug Discovery and Development
- 5.2.3 Others
-
5.3 By End User
- 5.3.1 Hospitals
- 5.3.2 Research Laboratories
- 5.3.3 Diagnostic Laboratories
- 5.3.4 Others
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Thermo Fisher Scientific Inc.
- 6.1.2 Quest Diagnostics Incorporated
- 6.1.3 Laboratory Corporation of America Holdings
- 6.1.4 F. Hoffmann-La Roche Ltd.
- 6.1.5 Agilent Technologies, Inc.
- 6.1.6 Cardinal Health
- 6.1.7 Sakura Finetek USA, Inc.
- 6.1.8 NeoGenomics Laboratories, Inc.
- 6.1.9 BioGenex
- 6.1.10 Bio SB
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Anatomic Pathology Industry Segmentation
As per the scope of the report, anatomic pathology is a medical specialty that is concerned with the diagnosis of disease based on the microscopic, macroscopic, biochemical, immunologic, and molecular examination of organs and tissues. Anatomic pathology involves the visualization of human tissue under a microscope for proper diagnosis of a disease or a pathological condition. Microscopic examination of tissue samples with the help of one or more stains is a standard procedure performed in anatomic pathology. The anatomic pathology market is segmented by products & services (instruments, consumables, and services), applications (disease diagnosis, drug discovery and development, and other applications), end users (hospitals, research laboratories, diagnostic laboratories, and other end users), and geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD) for the above segments.
| By Product & Services | Instruments | |
| Consumables | ||
| Services | ||
| By Application | Disease Diagnosis | |
| Drug Discovery and Development | ||
| Others | ||
| By End User | Hospitals | |
| Research Laboratories | ||
| Diagnostic Laboratories | ||
| Others | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Anatomic Pathology Market Research FAQs
What is the current Global Anatomic Pathology Market size?
The Global Anatomic Pathology Market is projected to register a CAGR of 6.5% during the forecast period (2024-2029)
Who are the key players in Global Anatomic Pathology Market?
Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, F. Hoffmann-La Roche Ltd., Laboratory Corporation of America Holdings and Agilent Technologies, Inc. are the major companies operating in the Global Anatomic Pathology Market.
Which is the fastest growing region in Global Anatomic Pathology Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Anatomic Pathology Market?
In 2024, the North America accounts for the largest market share in Global Anatomic Pathology Market.
What years does this Global Anatomic Pathology Market cover?
The report covers the Global Anatomic Pathology Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Anatomic Pathology Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Anatomic Pathology Industry Report
Statistics for the 2024 Anatomic Pathology market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Anatomic Pathology analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
